David Chang, PhDChief Executive Officer

Nov. 24, 2017

1

MTI Presentation

• Privately held diagnostics company headquartered in Edmonton, Alberta, Canada

• Founded in May 2010 as a spin-off from University of Alberta

• Developed breakthrough product platform based on metabolomics

• Lead product is PolypDxTM, a non-invasive diagnostic urine test for adenomatous polyp detection – The Precursor to Colorectal Cancer.

2

MTI Company Overview

3

MTI Team

Jean ForsytheProject Coordinator

Lu Deng, PhDSenior Scientist

David Chang, PhDChief Executive Officer

Dr. Haili WangChief Scientific Officer

Dr. Richard FedorakPresident and Chief

Medical Officer

4

PolypDxTM Opportunity

3rd most common cancer 2nd most frequent cause of cancer-

related deaths

>130,000 new cases of CRC every year 50,000 Deaths Annually

$14B spent annually treating colon cancer

Recommends that 89 million Americans be screened for colon cancer

1.3M new cases worldwide in 2012

Global rates rising due to lifestyle changes

International World Cancer Research Fund predicts 2.4M cases of CRC by 2035

4th most common cancer >300,000 new cases of CRC every year 360 million people ages 50-75 to be

screened

345,000 new cases in 2012

5

CRC – Early Screening is Key

Zau

ber

, A.G

.; W

inaw

er, S

.J.;

O'B

rien

, M

.J.;

Sch

apir

o ,

M.;

et

al.

New

En

gla

nd

Jo

urn

al o

f M

edic

ine

20

12

, 36

6, 6

87

-69

6.

Worldwide screening programs are currently in place to screen patients with colonoscopies.Currently many programs use a fecal based screening test to triage patients for colonoscopies.

Our product PolypDx™ to be used as a screening test triage the right patients for colonoscopies.PolypDx™ addresses two major issues:1) PolypDx™ is specifically designed for the detection of adenomatous polyps.2) Being a simple urine test, PolypDx™ will increase compliance of screening.

6

Metabolomics Biomarker Discovery Platform

2 Clinical TrialsCanada: 1200 patientsChina: 1000 patients3 key peer reviewed publications

Wang H, Tso V, Wong C, Sadowski D, Fedorak RN. Clin Transl Gastroenterol. 2014;5:e54.Deng L, Chang D, Foshaug RR, Eisner R, Tso VK, Wishart DS, Fedorak RN. Metabolites 2017;7.Deng L, Fang H, Tso VK, Sun Y, Foshaug RR, Krahn SC, et al. Int J Colorectal Dis 2017;32:741-3.

7

PolypDx™

Our product:

Annual check up forpatients ages 50-74

Urine samples collected and analyzed in a central laboratory

Patients with positive results are directed for polypectomy

Colorectal Cancer is prevented!

8

PolypDxTM Competitive AnalysisFIT

Matrix Stool Blood Stool Urine

Primary Purpose

Cancer Detection Cancer Detection Cancer DetectionCancer PREVENTION

Sensitivity

92% - CRC42% - AdvancedPrecancerous Lesions17% - Non-advanced adenomas

68% - CRC

50-87% - CRC20-67% - advancedadenomas13-26% - adenomas

52.9% - Adenomas70.5% - CRC

Specificity 87% 80% 93-98% 80.0%

DetectingDNA mutations & methylation, hemoglobin, Beta actin

Methylated Septin9 DNA

Hemoglobin 3 Metabolites

Methodology DNA DNA/PCR ImmunochemicalMetabolomics & LC-MS/MS

Clinical Trial10,000 Patients; 65 w/CRC

7,941 Patients enrolled; Performance validated in 1,554; 44 w/CRC

various studies1000 Patients; 243 w/Adenoma122 w/CRC

Cost (USD) $599 $300 $20 $399

9

MTI Development Milestones

Correlated analytes

Test algorithm developed Internal Validation

of Test algorithm

Closed Seed Round financing

Engaged AHS Labs to develop and optimize clinical protocol

Completed study with DynaLIFE Dx

Approval for logistics trial with AHS (Lethbridge, AB) supported by ACPLF through AIHS

Launch of PolypDxTM

with Atlantic Diagnostic Laboratories (ADL)

Clinical pilot with AHS Labs

Incorporation of Metabolomic

Technologies Inc.(May 6, 2010)

U.S. Provisional Patent Application filed

International Patent filed

Initiate HTP platform evaluation with DynaLIFE Dx

Agreement with BGI to conduct trials in China

Secured GoA-EAEfunding

Initiate clinical trial with BGI

HTP assessment through Custom Biologics

Secured NRC-IRAP Phase I

funding

Secured MDPD funding

External Validation of Test

algorithm

Trial attached to Edmonton Colon Cancer Screening Program (SCOPE)(2005-2012)

Submitted NRC-IRAP Phase II

2008 2009201720162015

20142013201220112010 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2

3 Metabolites NMR test complete

Replicated 3 Metabolites NMR test in Mass Spec platform

Methods development and validation of MS test

Development of LDT in CLIA labs

Begin CPT code process

Ramp up of US sales force

US pilots at 3 university

cancer hospitals

Complete trial and testing in

China

LIS Development with SpiekerPoint to deploy algorithm

Development and verification of test on Waters FDA approved instruments

2nd

agreement signed

2018

Secure joint venture partner in China

Establish Medical Advisory Board

Multi-site CFDA trial in China

• Operational partner – License agreement with Atlantic Diagnositic Laboratories

• Sales and distribution – Atlantic Diagnostic Laboratories and AnyLabTestNow

• Reimbursement pathway – C.M.S. codemap process in progress

• Utilization pilots underway in USC, Sloan Kettering, Jefferson University

10

US Business Development

11

PolypDxTM Business Development – North America

Currently selling in 16 US states

• Seeking partner for JV to help with:

– Regulatory

– Manufacturing

– Sales and Marketing/Distribution

– Reimbursement

• In discussions with different potential partners

12

China Business Development

13

PolypDxTM Business Development - China

14